Transforming molecular information
Go to content
Contact
IntegraGen on Twitter
IntegraGen on LinkedIn
IntegraGen - RSS feed
About Us
Company Overview
Management Team
Board of Directors
IntegraGen Genomics
Oncology
miRpredX 31-3p
miR‐31‐3p and colorectal cancer
miR-31-3p presentation and publications
Scientific Advisors
What are microRNA’s?
ICE Project
Lung Cancer
Oncology News
Autism
What is Autism Spectrum Disorder?
The Genetics of Autism
The ARISk Test
Autism Publications
News and Events
Press releases
Latest News
Upcoming Events
Investors
Corporate Presentations
Share Information
Number of shares and voting rights
Press releases
Calendar for Publications
Financial Documents
Financial Reports
Liquidity Contract
Shareholder Meetings
Investor Contacts
Join our mailing list
Contact Us
Office locations
Need Directions?
Contact form
Join our mailing list
Careers
Learn more »
Experts in genome analysis
and bioinformatics
Learn more »
Helping to personalize the care of cancer patients
Oncology biomarker discovery and development
Learn more »
IntegraGen presents positive data at 2016 ASCO meeting on the role of microRNA biomarker miR-31-3p
Learn more »
IntegraGen is a leader in genome analysis and the development and commercialization of molecular diagnostic tests for autism and oncology.
Genomic Services
"Helping you to find"
Learn more
Oncology Biomarkers and Bioinformatics
Explore our efforts to identify genetic markers and create software tools which can help to personalize cancer care
Learn more
Investors
Learn more about IntegraGen
Learn more
Latest news
// Archive
News
IntegraGen to attend 2017 BIO International Convention in San Diego
Press releases
Notice of publication of annual financial report
Press releases
IntegraGen Announces 2016 Annual Results: Increase in operating revenues and significant improvement in operating income (+22%)
By closing this message or navigating within the website, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.
Ok
